{"product_id":"tesamorelin-10mg","title":"Tesamorelin 10mg","description":"\u003cdiv style=\"background:#e7f4ee;border:1px solid #bfe3d2;border-left:4px solid #0e7a54;border-radius:14px;padding:16px 18px;margin:0 0 20px\"\u003e\n\u003cdiv style=\"font-weight:600;color:#0e7a54;font-size:15px;line-height:1.4;margin:0 0 8px\"\u003e✓ Third-party tested — batch CS-te10-0616\u003c\/div\u003e\n\u003cp style=\"margin:0 0 8px;color:#16201a;font-size:15px;line-height:1.6\"\u003eThis lot was assayed by \u003cstrong\u003eJanoshik Analytical\u003c\/strong\u003e (report #198440, analysis conducted 1 July 2026) at \u003cstrong\u003e99.174% purity\u003c\/strong\u003e, with a \u003cstrong\u003emeasured peptide content of 11.56 mg\u003c\/strong\u003e against a 10 mg nominal fill.\u003c\/p\u003e\n\u003cp style=\"margin:0;color:#5a6157;font-size:15px;line-height:1.6\"\u003e\u003ca href=\"\/pages\/lab-results\" style=\"color:#0e7a54;font-weight:600;text-decoration:underline\"\u003eView the batch COA\u003c\/a\u003e · \u003cspan style=\"color:#5a6157\"\u003eTestides (Toronto) confirmation pending\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cp style=\"margin:0 0 16px;color:#16201a;font-size:15px;line-height:1.65\"\u003e\u003cstrong\u003eTesamorelin (TH9507) is the complete 44-amino-acid sequence of human growth hormone-releasing hormone carrying a single trans-3-hexenoyl group on its N-terminal tyrosine, supplied here as 10 mg of lyophilised powder for laboratory research.\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp style=\"margin:0 0 14px;color:#5a6157;font-size:15px;line-height:1.65\"\u003eStructurally it is not a truncated or re-engineered GHRH. It is the full, unaltered hGRF(1-44)NH₂ backbone — \u003cspan style=\"font-family:ui-monospace,Menlo,monospace;font-size:15px;color:#16201a\"\u003eYADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL\u003c\/span\u003e, C-terminally amidated — with exactly one covalent change: a six-carbon acyl chain bearing a double bond at position 3, amide-linked to the α-amino group of Tyr¹, which is how the FDA prescribing information describes it. The parent molecule is endogenous human GHRH, GRF(1-44)-NH₂ (INN somatorelin). CAS \u003cstrong\u003e218949-48-5\u003c\/strong\u003e (free base), formula C₂₂₁H₃₆₆N₇₂O₆₇S, molecular weight \u003cstrong\u003e5135.9 Da\u003c\/strong\u003e; the single sulfur is the methionine at position 27. Each vial contains 10 mg of lyophilised peptide.\u003c\/p\u003e\n\n\u003cp style=\"margin:0 0 14px;color:#5a6157;font-size:15px;line-height:1.65\"\u003eThe modification addresses a specific liability. The Tyr¹-Ala² dipeptide of native GHRH is the cleavage site for dipeptidyl peptidase-4, the dominant route of GHRH inactivation in plasma, and acylating that terminus sterically obstructs the cleavage. That is the established design rationale and is standard across N-terminally acylated GHRH analogues, but we could not locate an open primary paper measuring tesamorelin's DPP-4 resistance head-to-head against native GHRH, so we present it as rationale rather than as a cited measurement. Affinity is not traded for stability: the label states that in vitro, tesamorelin binds and stimulates human GRF receptors with potency similar to endogenous GRF.\u003c\/p\u003e\n\n\u003cp style=\"margin:0 0 14px;color:#5a6157;font-size:15px;line-height:1.65\"\u003eWhat makes it unusual as a reagent is the depth of its human record — it is the only GHRH analogue with an approved pharmaceutical product, phase III trials, published pharmacokinetics and a full adverse-event table. Read honestly, that record is mixed: the European application was withdrawn before approval, the Canadian listing has been cancelled, a reformulation was rejected once on stability grounds, and the two most recent cognition trials were negative. All of it is below. The vial is supplied strictly as a laboratory reagent; the clinical data exist only because a licensed product was developed from the same molecule under regulatory oversight.\u003c\/p\u003e\n\n\u003cdiv style=\"margin-top:20px;margin-bottom:4px;padding:14px 16px;background:#f0faf5;border-left:4px solid #0f6e56;border-radius:0 8px 8px 0\"\u003e\u003cp style=\"margin:0;font-size:14px;color:#1a1a1a\"\u003e\u003cstrong\u003eFor laboratory and research use only.\u003c\/strong\u003e Not for human consumption, veterinary use, or therapeutic application. Not approved by Health Canada. We do not provide preparation, dilution or administration guidance for any compound we sell.\u003c\/p\u003e\u003c\/div\u003e\n\n\u003ch2 style=\"font-size:19px;font-weight:600;color:#16201a;margin:28px 0 12px;padding-left:12px;border-left:3px solid #2f3d2a\"\u003eSpecifications\u003c\/h2\u003e\n\n\u003ctable style=\"width:100%;border-collapse:collapse;font-size:15px;line-height:1.55\"\u003e\n\u003ctbody\u003e\n\u003ctr style=\"background:#fbfaf7\"\u003e\n\u003cth style=\"text-align:left;padding:10px 12px;border:1px solid #e7e6e0;color:#16201a;font-weight:600;width:38%\"\u003eCompound\u003c\/th\u003e\n\u003ctd style=\"padding:10px 12px;border:1px solid #e7e6e0;color:#5a6157\"\u003eTesamorelin, lyophilised powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left;padding:10px 12px;border:1px solid #e7e6e0;color:#16201a;font-weight:600\"\u003eSynonyms \/ development code\u003c\/th\u003e\n\u003ctd style=\"padding:10px 12px;border:1px solid #e7e6e0;color:#5a6157\"\u003eTH9507 (TH-9507); trans-3-hexenoyl-hGRF(1-44)-NH₂. Product brands: EGRIFTA, EGRIFTA SV, EGRIFTA WR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#fbfaf7\"\u003e\n\u003cth style=\"text-align:left;padding:10px 12px;border:1px solid #e7e6e0;color:#16201a;font-weight:600\"\u003eCompound class\u003c\/th\u003e\n\u003ctd style=\"padding:10px 12px;border:1px solid #e7e6e0;color:#5a6157\"\u003eN-terminally acylated GHRH analogue; GHRHR agonist\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left;padding:10px 12px;border:1px solid #e7e6e0;color:#16201a;font-weight:600\"\u003eCAS number\u003c\/th\u003e\n\u003ctd style=\"padding:10px 12px;border:1px solid #e7e6e0;color:#5a6157\"\u003e218949-48-5 (free base)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#fbfaf7\"\u003e\n\u003cth style=\"text-align:left;padding:10px 12px;border:1px solid #e7e6e0;color:#16201a;font-weight:600\"\u003eMolecular formula\u003c\/th\u003e\n\u003ctd style=\"padding:10px 12px;border:1px solid #e7e6e0;color:#5a6157\"\u003eC₂₂₁H₃₆₆N₇₂O₆₇S (free base)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left;padding:10px 12px;border:1px solid #e7e6e0;color:#16201a;font-weight:600\"\u003eMolecular weight\u003c\/th\u003e\n\u003ctd style=\"padding:10px 12px;border:1px solid #e7e6e0;color:#5a6157\"\u003e5135.9 Da (free base)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#fbfaf7\"\u003e\n\u003cth style=\"text-align:left;padding:10px 12px;border:1px solid #e7e6e0;color:#16201a;font-weight:600\"\u003eSequence length\u003c\/th\u003e\n\u003ctd style=\"padding:10px 12px;border:1px solid #e7e6e0;color:#5a6157\"\u003e44 amino acids, C-terminally amidated, plus one N-terminal trans-3-hexenoyl group on Tyr¹\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left;padding:10px 12px;border:1px solid #e7e6e0;color:#16201a;font-weight:600\"\u003eVial contents\u003c\/th\u003e\n\u003ctd style=\"padding:10px 12px;border:1px solid #e7e6e0;color:#5a6157\"\u003e10 mg lyophilised tesamorelin, sealed vial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#fbfaf7\"\u003e\n\u003cth style=\"text-align:left;padding:10px 12px;border:1px solid #e7e6e0;color:#16201a;font-weight:600\"\u003eCurrent lot\u003c\/th\u003e\n\u003ctd style=\"padding:10px 12px;border:1px solid #e7e6e0;color:#5a6157\"\u003eCS-te10-0616 (Janoshik report #198440)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left;padding:10px 12px;border:1px solid #e7e6e0;color:#16201a;font-weight:600\"\u003eVerified purity\u003c\/th\u003e\n\u003ctd style=\"padding:10px 12px;border:1px solid #e7e6e0;color:#0e7a54;font-weight:600\"\u003e99.174%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#fbfaf7\"\u003e\n\u003cth style=\"text-align:left;padding:10px 12px;border:1px solid #e7e6e0;color:#16201a;font-weight:600\"\u003eMeasured content\u003c\/th\u003e\n\u003ctd style=\"padding:10px 12px;border:1px solid #e7e6e0;color:#0e7a54;font-weight:600\"\u003e11.56 mg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left;padding:10px 12px;border:1px solid #e7e6e0;color:#16201a;font-weight:600\"\u003eTest method\u003c\/th\u003e\n\u003ctd style=\"padding:10px 12px;border:1px solid #e7e6e0;color:#5a6157\"\u003eHPLC purity and quantitative content; analysis conducted 1 July 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#fbfaf7\"\u003e\n\u003cth style=\"text-align:left;padding:10px 12px;border:1px solid #e7e6e0;color:#16201a;font-weight:600\"\u003eTesting laboratory\u003c\/th\u003e\n\u003ctd style=\"padding:10px 12px;border:1px solid #e7e6e0;color:#5a6157\"\u003eJanoshik Analytical, independent third party — \u003ca href=\"\/pages\/lab-results\" style=\"color:#0e7a54;text-decoration:underline\"\u003ereport #198440\u003c\/a\u003e. Testides (Toronto) confirmation pending.\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left;padding:10px 12px;border:1px solid #e7e6e0;color:#16201a;font-weight:600\"\u003eStorage\u003c\/th\u003e\n\u003ctd style=\"padding:10px 12px;border:1px solid #e7e6e0;color:#5a6157\"\u003eLyophilised: −20 °C long-term, 2–8 °C short-term, desiccated and protected from light\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#fbfaf7\"\u003e\n\u003cth style=\"text-align:left;padding:10px 12px;border:1px solid #e7e6e0;color:#16201a;font-weight:600\"\u003eResearch applications\u003c\/th\u003e\n\u003ctd style=\"padding:10px 12px;border:1px solid #e7e6e0;color:#5a6157\"\u003eGHRHR binding and cAMP functional assays; somatotroph culture; GHRHR versus GHS-R1a comparative pharmacology; plasma stability and peptidase work; adipose-depot and hepatic-steatosis models; anti-drug-antibody assay development; LC-MS\/MS and RP-HPLC method development\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left;padding:10px 12px;border:1px solid #e7e6e0;color:#16201a;font-weight:600\"\u003eRelated compounds\u003c\/th\u003e\n\u003ctd style=\"padding:10px 12px;border:1px solid #e7e6e0;color:#5a6157\"\u003e\n\u003ca href=\"\/products\/ipamorelin-10mg\" style=\"color:#2f3d2a;text-decoration:underline\"\u003eIpamorelin 10mg\u003c\/a\u003e · \u003ca href=\"\/products\/cjc-1295-ipamorelin\" style=\"color:#2f3d2a;text-decoration:underline\"\u003eCJC-1295 \/ Ipamorelin\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#fbfaf7\"\u003e\n\u003cth style=\"text-align:left;padding:10px 12px;border:1px solid #e7e6e0;color:#16201a;font-weight:600\"\u003eShips from\u003c\/th\u003e\n\u003ctd style=\"padding:10px 12px;border:1px solid #e7e6e0;color:#5a6157\"\u003eBritish Columbia, Canada — free tracked shipping Canada-wide, dispatched within 48 hours\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left;padding:10px 12px;border:1px solid #e7e6e0;color:#16201a;font-weight:600\"\u003eIntended use\u003c\/th\u003e\n\u003ctd style=\"padding:10px 12px;border:1px solid #e7e6e0;color:#5a6157\"\u003eLaboratory research only — in vitro and preclinical. Not a drug; not for human or veterinary use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cdetails style=\"border:1px solid #e7e6e0;border-radius:14px;margin:24px 0 10px;background:#fff\"\u003e\n\u003csummary style=\"cursor:pointer;padding:14px 16px;font-weight:600;color:#16201a;font-size:15px;line-height:1.45\"\u003eHow does tesamorelin work at the receptor level, and does it preserve natural GH pulses?\u003c\/summary\u003e\n\u003cdiv style=\"padding:0 16px 16px\"\u003e\n\u003cp style=\"margin:0 0 12px;color:#5a6157;font-size:15px;line-height:1.65\"\u003eTesamorelin is an agonist at the growth hormone-releasing hormone receptor (GHRHR), a class-B1 GPCR on pituitary somatotrophs. Occupancy couples through Gs and adenylyl cyclase to raise intracellular cAMP, driving both the \u003cem\u003esynthesis\u003c\/em\u003e and the \u003cem\u003erelease\u003c\/em\u003e of growth hormone, which drives hepatic IGF-1 production.\u003c\/p\u003e\n\u003cp style=\"margin:0 0 12px;color:#5a6157;font-size:15px;line-height:1.65\"\u003eWhether pulsatile architecture survives that stimulation was measured, not assumed. Stanley et al. (\u003cem\u003eJ Clin Endocrinol Metab\u003c\/em\u003e 2011;96(1):150-158) ran overnight frequent GH sampling in 13 healthy men after two weeks, measuring mean overnight GH, log₁₀ GH peak area, basal secretion rate, IGF-1 and insulin-stimulated glucose uptake. The pattern reported stayed pulsatile: existing pulses were amplified rather than replaced by a flat elevated plateau.\u003c\/p\u003e\n\u003cp style=\"margin:0;color:#5a6157;font-size:15px;line-height:1.65\"\u003eBecause the stimulus is applied upstream at the pituitary, the effect remains subject to somatostatin tone and IGF-1 negative feedback — the brake stays connected and the response is self-limiting. Exogenous recombinant GH, by contrast, abolishes pulsatility and suppresses endogenous secretion. That is why a GHRH analogue is the right probe for physiological axis regulation rather than for GH exposure alone.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/details\u003e\n\n\u003cdetails style=\"border:1px solid #e7e6e0;border-radius:14px;margin:0 0 10px;background:#fff\"\u003e\n\u003csummary style=\"cursor:pointer;padding:14px 16px;font-weight:600;color:#16201a;font-size:15px;line-height:1.45\"\u003eIs tesamorelin approved in Canada or the United States?\u003c\/summary\u003e\n\u003cdiv style=\"padding:0 16px 16px\"\u003e\n\u003cp style=\"margin:0 0 12px;color:#5a6157;font-size:15px;line-height:1.65\"\u003e\u003cstrong\u003eHealth Canada initially refused it.\u003c\/strong\u003e The original New Drug Submission received a Notice of Non-Compliance – Withdrawal over diabetogenic effect and IGF-1-related carcinogenicity concerns. Authorisation followed only after an expert \u003cstrong\u003eReconsideration Panel in August 2013\u003c\/strong\u003e: a Notice of Compliance issued \u003cstrong\u003e29 April 2014\u003c\/strong\u003e (NDS 131836, brand EGRIFTA, sponsor Theratechnologies Inc.), with restricted conditions of use including mandatory IGF-1 monitoring, and an indication narrower than the American one.\u003c\/p\u003e\n\u003cp style=\"margin:0 0 12px;color:#5a6157;font-size:15px;line-height:1.65\"\u003e\u003cstrong\u003eIt was marketed in Canada from 23 June 2015, and has since been withdrawn.\u003c\/strong\u003e Verified against the Health Canada Drug Product Database:\u003c\/p\u003e\n\u003cdiv style=\"border:1px solid #eeddbc;background:#faf2e2;border-radius:14px;padding:14px 16px;margin:0 0 12px\"\u003e\n\u003cp style=\"margin:0 0 8px;color:#8a6318;font-size:15px;line-height:1.6\"\u003e\u003cstrong\u003eDIN 02438712\u003c\/strong\u003e — EGRIFTA 1 mg\/vial · first marketed 2015-06-23 · \u003cstrong\u003eCancelled Post Market, 30 September 2022\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp style=\"margin:0 0 8px;color:#8a6318;font-size:15px;line-height:1.6\"\u003e\u003cstrong\u003eDIN 02423677\u003c\/strong\u003e — EGRIFTA 2 mg\/vial · never marketed · \u003cstrong\u003eCancelled Pre Market, 13 July 2023\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp style=\"margin:0;color:#8a6318;font-size:15px;line-height:1.6\"\u003eThere is no currently marketed tesamorelin product in Canada. EGRIFTA SV and EGRIFTA WR have never been authorised here.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cp style=\"margin:0 0 12px;color:#5a6157;font-size:15px;line-height:1.65\"\u003e\u003cstrong\u003eUnited States.\u003c\/strong\u003e EGRIFTA was approved \u003cstrong\u003e27 November 2010\u003c\/strong\u003e, EGRIFTA SV in 2019, and \u003cstrong\u003eEGRIFTA WR\u003c\/strong\u003e on \u003cstrong\u003e25 March 2025\u003c\/strong\u003e, available from 5 September 2025. That approval was not smooth: the FDA issued a \u003cstrong\u003eComplete Response Letter on 24 January 2024\u003c\/strong\u003e on chemistry, manufacturing and controls grounds — impurities, microbiological assays, and the stability of both the lyophilised and the reconstituted product — plus a request for more immunogenicity data on the concentrated formulation. Efficacy and bioequivalence were not challenged. A contract-manufacturing shutdown separately caused an EGRIFTA SV shortage from mid-January 2025.\u003c\/p\u003e\n\u003cp style=\"margin:0 0 12px;color:#5a6157;font-size:15px;line-height:1.65\"\u003e\u003cstrong\u003eEuropean Union: never approved.\u003c\/strong\u003e Theratechnologies withdrew its marketing authorisation application in \u003cstrong\u003eJune 2012\u003c\/strong\u003e, citing the absence of safety data beyond 48 weeks on elevated IGF-1 and the absence of a cardiovascular endpoint.\u003c\/p\u003e\n\u003cp style=\"margin:0 0 12px;color:#5a6157;font-size:15px;line-height:1.65\"\u003e\u003cstrong\u003eElsewhere: we do not know.\u003c\/strong\u003e We found no evidence either way on the United Kingdom, Australia, Japan or China, and will not call tesamorelin “US-only” on absent evidence. What we can state: approved in the US, approved and no longer marketed in Canada, never approved in the EU.\u003c\/p\u003e\n\u003cp style=\"margin:0;color:#5a6157;font-size:15px;line-height:1.65\"\u003eNone of this makes the vial on this page an authorised drug — it is an unapproved research reagent. Tesamorelin is also named explicitly on the WADA Prohibited List under section S2, prohibited at all times.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/details\u003e\n\n\u003cdetails style=\"border:1px solid #e7e6e0;border-radius:14px;margin:0 0 10px;background:#fff\"\u003e\n\u003csummary style=\"cursor:pointer;padding:14px 16px;font-weight:600;color:#16201a;font-size:15px;line-height:1.45\"\u003eTesamorelin vs ipamorelin — which limb of the GH axis does each one probe?\u003c\/summary\u003e\n\u003cdiv style=\"padding:0 16px 16px\"\u003e\n\u003cp style=\"margin:0 0 12px;color:#5a6157;font-size:15px;line-height:1.65\"\u003e“Which is better” is the wrong question. These compounds act on different receptors, through different second messengers, on the same cell — which is why co-administration studies of the two classes exist at all.\u003c\/p\u003e\n\u003cdiv style=\"border:1px solid #e7e6e0;border-radius:14px;padding:14px 16px;margin:0 0 12px;background:#f6f8f5\"\u003e\n\u003cp style=\"margin:0 0 6px;color:#16201a;font-size:15px;line-height:1.5;font-weight:600\"\u003eTesamorelin — GHRH analogue\u003c\/p\u003e\n\u003cp style=\"margin:0;color:#5a6157;font-size:15px;line-height:1.6\"\u003eGHRHR, Gs\/cAMP. Drives GH \u003cem\u003esynthesis and\u003c\/em\u003e release, and sets pulse amplitude. Opposed by hypothalamic somatostatin, so endogenous negative feedback stays intact and caps the response. Pulsatility amplified and preserved (measured, Stanley 2011). Regulatory-grade human record: phase III RCTs, an approved product, published PK.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv style=\"border:1px solid #e7e6e0;border-radius:14px;padding:14px 16px;margin:0 0 12px;background:#f6f8f5\"\u003e\n\u003cp style=\"margin:0 0 6px;color:#16201a;font-size:15px;line-height:1.5;font-weight:600\"\u003eIpamorelin — GHS-R1a agonist\u003c\/p\u003e\n\u003cp style=\"margin:0;color:#5a6157;font-size:15px;line-height:1.6\"\u003eGHS-R1a, the ghrelin receptor, Gq\/PLC\/IP₃-Ca²⁺. Triggers release of already-made GH and functionally antagonises somatostatin tone rather than working against it. Different ceiling behaviour, classically synergistic with a GHRH analogue. No approved product and no phase III human efficacy data.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cp style=\"margin:0;color:#5a6157;font-size:15px;line-height:1.65\"\u003eThree design consequences. \u003cstrong\u003eComparator choice:\u003c\/strong\u003e work isolating GHRH-pathway signalling cannot use a ghrelin mimetic as its comparator, or vice versa — they are two arms of a synergy model, not substitutes. \u003cstrong\u003eConfound profile:\u003c\/strong\u003e GHS-R1a is also the orexigenic receptor and is expressed outside the pituitary, so ghrelin-receptor agonists carry food-intake and GI-motility confounds a GHRHR agonist does not. \u003cstrong\u003eEvidence asymmetry:\u003c\/strong\u003e tesamorelin is the only compound in this class with regulatory-grade human characterisation. If a GHS-R1a probe is what the protocol needs, tesamorelin is the wrong reagent — see \u003ca href=\"\/products\/ipamorelin-10mg\" style=\"color:#2f3d2a;text-decoration:underline\"\u003eIpamorelin 10mg\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/details\u003e\n\n\u003cdetails style=\"border:1px solid #e7e6e0;border-radius:14px;margin:0 0 10px;background:#fff\"\u003e\n\u003csummary style=\"cursor:pointer;padding:14px 16px;font-weight:600;color:#16201a;font-size:15px;line-height:1.45\"\u003eWhat has been published on tesamorelin, and what are the limits?\u003c\/summary\u003e\n\u003cdiv style=\"padding:0 16px 16px\"\u003e\n\u003cp style=\"margin:0 0 12px;color:#5a6157;font-size:15px;line-height:1.65\"\u003e\u003cstrong\u003eNot a weight-loss agent.\u003c\/strong\u003e The FDA label carries an explicit Limitation of Use: not indicated for weight loss management. Makimura 2012, the main non-HIV randomised trial, found \u003cstrong\u003eno significant weight change over 12 months (P = 0.52)\u003c\/strong\u003e despite a measured visceral fat effect in the same study; Clemmons 2017 found \u003cstrong\u003eno change in weight, BMI, body fat or waist circumference\u003c\/strong\u003e over 12 weeks, and no change in glycaemic control. The effect is compartment redistribution, not mass reduction.\u003c\/p\u003e\n\u003cp style=\"margin:0 0 12px;color:#5a6157;font-size:15px;line-height:1.65\"\u003e\u003cstrong\u003eNo cardiovascular outcome benefit demonstrated.\u003c\/strong\u003e “Long-term cardiovascular safety and benefit have not been studied” is a label Limitation of Use, and the missing cardiovascular endpoint was a stated reason for the 2012 EU withdrawal. The carotid intima-media thickness change reported in Makimura 2012 is a surrogate, not an outcome.\u003c\/p\u003e\n\u003cp style=\"margin:0 0 12px;color:#5a6157;font-size:15px;line-height:1.65\"\u003e\u003cstrong\u003eCognition is not established, and the two most recent trials are negative.\u003c\/strong\u003e Baker et al. (\u003cem\u003eArch Neurol\u003c\/em\u003e 2012) is the positive signal everyone cites: 137 completers aged 55-87, 20 weeks, measuring cognitive test performance and IGF-1 in healthy and mild-cognitive-impairment groups, with the authors themselves calling for larger trials. Those have partly happened and have not replicated it. Ellis et al. (\u003cem\u003eJ Infect Dis\u003c\/em\u003e 2025) randomised 73 people with HIV and abdominal obesity over six months and missed the primary endpoint — \u003cstrong\u003ebetween-group P = 0.673\u003c\/strong\u003e — concluding no clear benefit. Stewart et al. (\u003cem\u003eeNeurologicalSci\u003c\/em\u003e 2026), a 22-participant double-blind low-dose pilot, reported that treatment “was not directly linked with significant changes in study measures”.\u003c\/p\u003e\n\u003cp style=\"margin:0 0 12px;color:#5a6157;font-size:15px;line-height:1.65\"\u003e\u003cstrong\u003eLiver histology is unproven.\u003c\/strong\u003e The 12-month \u003cem\u003eLancet HIV\u003c\/em\u003e 2019 trial measured hepatic fat fraction by imaging; its authors conclude only that tesamorelin “might be beneficial” and that further studies are needed on liver \u003cem\u003ehistology\u003c\/em\u003e. NASH resolution and fibrosis outcomes are not established. A general-population NASH programme was announced in September 2020; we found no published results and no discontinuation notice, and claim neither.\u003c\/p\u003e\n\u003cp style=\"margin:0;color:#5a6157;font-size:15px;line-height:1.65\"\u003e\u003cstrong\u003ePopulation limits.\u003c\/strong\u003e Almost all human efficacy data come from people with HIV and lipodystrophy; Makimura 2012 is the main exception, and there are no paediatric data. A 2026 meta-analysis of tesamorelin RCTs exists (PMID 41545261); we have not verified its pooled estimates and quote no numbers from it.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/details\u003e\n\n\u003cdetails style=\"border:1px solid #e7e6e0;border-radius:14px;margin:0 0 10px;background:#fff\"\u003e\n\u003csummary style=\"cursor:pointer;padding:14px 16px;font-weight:600;color:#16201a;font-size:15px;line-height:1.45\"\u003eWhat happens when tesamorelin is discontinued?\u003c\/summary\u003e\n\u003cdiv style=\"padding:0 16px 16px\"\u003e\n\u003cp style=\"margin:0 0 12px;color:#5a6157;font-size:15px;line-height:1.65\"\u003eThe visceral fat comes back, and this is measured rather than inferred. Falutz et al. (\u003cem\u003eAIDS\u003c\/em\u003e 2008;22(14):1719-1728) re-randomised 410 participants at week 26. Those continuing on tesamorelin sustained the visceral adipose tissue change over 52 weeks; those switched to placebo \u003cstrong\u003ereaccumulated VAT\u003c\/strong\u003e across weeks 26 to 52. The authors conclude that the effects do not last beyond the duration of treatment.\u003c\/p\u003e\n\u003cp style=\"margin:0;color:#5a6157;font-size:15px;line-height:1.65\"\u003eNo published evidence shows a durable post-treatment benefit, and the mechanism makes that unsurprising: a secretagogue acting on an intact, feedback-regulated axis leaves little trace once the stimulus is removed. Labelled fluid-retention effects conversely tend to resolve after stopping. Any protocol asking about persistence therefore needs an off-treatment arm.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/details\u003e\n\n\u003cdetails style=\"border:1px solid #e7e6e0;border-radius:14px;margin:0 0 10px;background:#fff\"\u003e\n\u003csummary style=\"cursor:pointer;padding:14px 16px;font-weight:600;color:#16201a;font-size:15px;line-height:1.45\"\u003eWhy do about half of treated subjects develop anti-tesamorelin antibodies?\u003c\/summary\u003e\n\u003cdiv style=\"padding:0 16px 16px\"\u003e\n\u003cp style=\"margin:0 0 12px;color:#5a6157;font-size:15px;line-height:1.65\"\u003eIn the clinical record documented in the FDA label, \u003cstrong\u003e49.5% of treated patients developed anti-tesamorelin IgG antibodies by 26 weeks\u003c\/strong\u003e and 47.4% by 52 weeks, with \u003cstrong\u003ecross-reactivity to endogenous GHRH in roughly 60%\u003c\/strong\u003e of antibody-positive patients. Antibody presence did not reduce the visceral fat or IGF-1 response. Of patients with hypersensitivity reactions, 85.2% were antibody-positive; labelled hypersensitivity reactions occurred in 3.6% overall.\u003c\/p\u003e\n\u003cp style=\"margin:0 0 12px;color:#5a6157;font-size:15px;line-height:1.65\"\u003eWhy that is interesting rather than merely a safety line: tesamorelin is a self-sequence peptide with one small non-native acyl modification, and it still elicits antibodies in about half of exposed subjects, much of it cross-reactive with the endogenous hormone — a well-quantified natural experiment in tolerance and epitope formation.\u003c\/p\u003e\n\u003cp style=\"margin:0;color:#5a6157;font-size:15px;line-height:1.65\"\u003eThat makes it a substantive model antigen for anti-drug-antibody assay development, analogue-versus-parent cross-reactivity, and epitope-mapping method work. It is also why the FDA requested more immunogenicity data when reviewing the concentrated formulation in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/details\u003e\n\n\u003cdetails style=\"border:1px solid #e7e6e0;border-radius:14px;margin:0 0 10px;background:#fff\"\u003e\n\u003csummary style=\"cursor:pointer;padding:14px 16px;font-weight:600;color:#16201a;font-size:15px;line-height:1.45\"\u003eWhat purity is this lot, and how do I read the COA?\u003c\/summary\u003e\n\u003cdiv style=\"padding:0 16px 16px\"\u003e\n\u003cp style=\"margin:0 0 12px;color:#5a6157;font-size:15px;line-height:1.65\"\u003eLot \u003cstrong\u003eCS-te10-0616\u003c\/strong\u003e was submitted to Janoshik Analytical, an independent third-party laboratory, and reported under \u003cstrong\u003ereport #198440\u003c\/strong\u003e, analysis conducted \u003cstrong\u003e1 July 2026\u003c\/strong\u003e: purity \u003cstrong style=\"color:#0e7a54\"\u003e99.174%\u003c\/strong\u003e, measured peptide content \u003cstrong style=\"color:#0e7a54\"\u003e11.56 mg\u003c\/strong\u003e against a 10 mg nominal fill. This is the Janoshik Analytical assay; Testides (Toronto) confirmation is still pending. Every current lot is indexed on our \u003ca href=\"\/pages\/lab-results\" style=\"color:#0e7a54;font-weight:600;text-decoration:underline\"\u003elab results page\u003c\/a\u003e.\u003c\/p\u003e\n\u003cp style=\"margin:0 0 12px;color:#5a6157;font-size:15px;line-height:1.65\"\u003eThose two figures do different jobs, and conflating them is the commonest error in reading a COA. \u003cstrong\u003ePurity\u003c\/strong\u003e is the proportion of peptide-containing material that is the target peptide, as resolved by HPLC; it says nothing about how much is in the vial. \u003cstrong\u003eContent\u003c\/strong\u003e is the quantitative mass determination; it says nothing about what the remainder is. A vial can be 99% pure and underfilled, or correctly filled and 90% pure — you need both, from the same lot, with the lot number matching the vial label. Full walkthrough: \u003ca href=\"\/blogs\/news\/how-to-read-peptide-coa\" style=\"color:#0e7a54;text-decoration:underline\"\u003ehow to read a peptide COA\u003c\/a\u003e.\u003c\/p\u003e\n\u003cp style=\"margin:0;color:#5a6157;font-size:15px;line-height:1.65\"\u003eOne caveat almost no supplier mentions: the pharmaceutical drug substance is the \u003cstrong\u003eacetate salt\u003c\/strong\u003e, the label formula being the free base plus roughly seven acetic acid equivalents — around 8% heavier. We do not print an acetate CAS number or acetate molecular weight as established, because the figures circulating online rest on a single secondary source and on arithmetic estimation rather than a primary measurement. Either way, a vial characterised by peptide content and one characterised by total salt mass are not the same quantity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/details\u003e\n\n\u003cdetails style=\"border:1px solid #e7e6e0;border-radius:14px;margin:0 0 10px;background:#fff\"\u003e\n\u003csummary style=\"cursor:pointer;padding:14px 16px;font-weight:600;color:#16201a;font-size:15px;line-height:1.45\"\u003eWhat is the half-life of tesamorelin?\u003c\/summary\u003e\n\u003cdiv style=\"padding:0 16px 16px\"\u003e\n\u003cp style=\"margin:0 0 12px;color:#5a6157;font-size:15px;line-height:1.65\"\u003eThe two label generations disagree, so we show both rather than pick one. The \u003cstrong\u003eEGRIFTA\u003c\/strong\u003e prescribing information, section 12.3, reports a terminal half-life after 14 days of subcutaneous administration of \u003cstrong\u003e26 minutes in healthy subjects and 38 minutes in HIV-infected patients\u003c\/strong\u003e. The later \u003cstrong\u003eEGRIFTA SV \/ EGRIFTA WR\u003c\/strong\u003e label states \u003cstrong\u003e8 minutes in healthy subjects\u003c\/strong\u003e. Both are label-sourced, and volume of distribution likewise differs across label versions (9.4–10.5 L\/kg versus 4.8 L\/kg). The widely copied “26 to 38 minutes” is one of these figures reproduced without the label version, formulation or route it belongs to.\u003c\/p\u003e\n\u003cp style=\"margin:0;color:#5a6157;font-size:15px;line-height:1.65\"\u003eWorth pairing with it: subcutaneous bioavailability is documented at \u003cstrong\u003eunder 4%\u003c\/strong\u003e. That is genuinely unusual, and it is why exposure and effect decouple so sharply here — a short plasma residence with very low systemic availability still produces sustained IGF-1 elevation, because the readout is a downstream secretory cascade rather than the peptide itself.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/details\u003e\n\n\u003cdetails style=\"border:1px solid #e7e6e0;border-radius:14px;margin:0 0 10px;background:#fff\"\u003e\n\u003csummary style=\"cursor:pointer;padding:14px 16px;font-weight:600;color:#16201a;font-size:15px;line-height:1.45\"\u003eIs tesamorelin the same compound as adipotide?\u003c\/summary\u003e\n\u003cdiv style=\"padding:0 16px 16px\"\u003e\n\u003cp style=\"margin:0;color:#5a6157;font-size:15px;line-height:1.65\"\u003eNo. The synonym list attached to CAS 218949-48-5 in at least one widely scraped chemical database carries contaminated entries, including “Adipotide\/FTTP”. Adipotide is an unrelated prohibitin-targeting peptidomimetic with a different structure, target and mechanism, so any listing reproducing a scraped synonym block publishes a false synonym. Two neighbouring corrections while we are here: tesamorelin is not sermorelin, which is the shorter GHRH(1-29)NH₂ fragment rather than tesamorelin’s parent; and EGRIFTA is not a different molecule, but the brand name of the product formulated from tesamorelin acetate.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/details\u003e\n\n\u003cdetails style=\"border:1px solid #e7e6e0;border-radius:14px;margin:0 0 10px;background:#fff\"\u003e\n\u003csummary style=\"cursor:pointer;padding:14px 16px;font-weight:600;color:#16201a;font-size:15px;line-height:1.45\"\u003eHow should lyophilised tesamorelin be stored, and does it need refrigeration?\u003c\/summary\u003e\n\u003cdiv style=\"padding:0 16px 16px\"\u003e\n\u003cp style=\"margin:0 0 12px;color:#5a6157;font-size:15px;line-height:1.65\"\u003eTwo answers circulate and contradict each other; both are correct for different materials. \u003cstrong\u003eThe approved pharmaceutical product is a room-temperature product.\u003c\/strong\u003e The FDA label directs storage of the lyophilised EGRIFTA and EGRIFTA SV vial at up to 25 °C, excursions permitted 15–30 °C, \u003cstrong\u003eprotected from light and kept in the original carton\u003c\/strong\u003e. EGRIFTA WR is likewise labelled 20–25 °C before reconstitution. The approved lyophilised drug product does not require refrigeration, which corrects a widespread vendor claim.\u003c\/p\u003e\n\u003cp style=\"margin:0 0 12px;color:#5a6157;font-size:15px;line-height:1.65\"\u003e\u003cstrong\u003eResearch convention for an unformulated peptide is colder, and the excipient package is why.\u003c\/strong\u003e The drug product is a stabilised formulation with a defined shelf life — mannitol in the 1 mg presentation; mannitol, sucrose, histidine and polysorbate 20 in the 2 mg. Those excipients do real work: bulking and cryoprotection, buffering, and in polysorbate 20’s case a surfactant mitigating interfacial and shear stress on a 44-residue peptide. An unformulated research peptide has none of that and no shelf-life study behind it, which is why the convention for lyophilised GHRH analogues is \u003cstrong\u003e−20 °C long-term and 2–8 °C short-term\u003c\/strong\u003e, desiccated and dark.\u003c\/p\u003e\n\u003cp style=\"margin:0 0 12px;color:#5a6157;font-size:15px;line-height:1.65\"\u003e\u003cstrong\u003eLight protection is label-mandated, not folklore\u003c\/strong\u003e — the instruction to keep the vial in its carton comes from the prescribing information. The structural rationale, two tyrosines plus an oxidation-prone methionine at position 27 and an alkene in the hexenoyl group, is our reading of the structure rather than a cited stability study, and we offer it as rationale only.\u003c\/p\u003e\n\u003cp style=\"margin:0 0 12px;color:#5a6157;font-size:15px;line-height:1.65\"\u003e\u003cstrong\u003eAvoid freeze-thaw cycling.\u003c\/strong\u003e Aliquot before freezing so a working stock is never repeatedly thawed, and do not freeze reconstituted material. Reconstituted stability is unusually formulation-dependent here: the older presentations are labelled for immediate use with an explicit instruction \u003cem\u003enot\u003c\/em\u003e to refrigerate the reconstituted solution, while EGRIFTA WR is labelled for up to 7 days at 20–25 °C — so any blanket claim about how long reconstituted tesamorelin lasts is unsupportable without naming the formulation. We could not verify a published formulation pH or isoelectric point and will not print a number for either.\u003c\/p\u003e\n\u003cp style=\"margin:0;color:#5a6157;font-size:15px;line-height:1.65\"\u003eFinally, stability here is a documented regulator-level weakness rather than a theoretical concern: the FDA’s January 2024 Complete Response Letter cited the stability of both the lyophilised and the reconstituted drug.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/details\u003e\n\n\u003cdetails style=\"border:1px solid #e7e6e0;border-radius:14px;margin:0 0 10px;background:#fff\"\u003e\n\u003csummary style=\"cursor:pointer;padding:14px 16px;font-weight:600;color:#16201a;font-size:15px;line-height:1.45\"\u003eHow fast do you ship, and is delivery free across Canada?\u003c\/summary\u003e\n\u003cdiv style=\"padding:0 16px 16px\"\u003e\n\u003cp style=\"margin:0 0 12px;color:#5a6157;font-size:15px;line-height:1.65\"\u003eShipping is \u003cstrong\u003efree and tracked, Canada-wide, with no minimum order\u003c\/strong\u003e. Orders are dispatched \u003cstrong\u003ewithin 48 hours\u003c\/strong\u003e, Monday to Friday, from our facility in \u003cstrong\u003eBritish Columbia\u003c\/strong\u003e. Because the vial is already in Canada there is no international leg, no customs clearance and no brokerage on a domestic order.\u003c\/p\u003e\n\u003cp style=\"margin:0;color:#5a6157;font-size:15px;line-height:1.65\"\u003eVials ship sealed, with the lot number on the label so it can be matched against the published certificate of analysis. Tracking is issued at dispatch. Current transit estimates are on our \u003ca href=\"\/pages\/shipping\" style=\"color:#2f3d2a;text-decoration:underline\"\u003eshipping page\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/details\u003e\n\n\u003cdetails style=\"border:1px solid #e7e6e0;border-radius:14px;margin:0 0 10px;background:#fff\"\u003e\n\u003csummary style=\"cursor:pointer;padding:14px 16px;font-weight:600;color:#16201a;font-size:15px;line-height:1.45\"\u003eWhat is your refund policy if a vial arrives damaged?\u003c\/summary\u003e\n\u003cdiv style=\"padding:0 16px 16px\"\u003e\n\u003cp style=\"margin:0 0 12px;color:#5a6157;font-size:15px;line-height:1.65\"\u003eReport damage in transit or non-delivery to \u003ca href=\"mailto:info@thepeptide.ca\" style=\"color:#2f3d2a;text-decoration:underline\"\u003einfo@thepeptide.ca\u003c\/a\u003e \u003cstrong\u003ewithin 48 hours of the expected delivery date\u003c\/strong\u003e, with photographs of the packaging and vial where applicable, and we will resolve it.\u003c\/p\u003e\n\u003cp style=\"margin:0 0 12px;color:#5a6157;font-size:15px;line-height:1.65\"\u003eSealed, unopened vials are exchangeable within \u003cstrong\u003e14 days\u003c\/strong\u003e of delivery. There are no refunds or exchanges on product that has been opened, reconstituted or otherwise prepared: once a seal is broken we cannot verify handling history, and a reagent of unknown temperature and light exposure is not one we will put back into circulation.\u003c\/p\u003e\n\u003cp style=\"margin:0;color:#5a6157;font-size:15px;line-height:1.65\"\u003eFull terms: \u003ca href=\"\/policies\/refund-policy\" style=\"color:#2f3d2a;text-decoration:underline\"\u003erefund policy\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/details\u003e\n\n\u003cdetails style=\"border:1px solid #e7e6e0;border-radius:14px;margin:0 0 10px;background:#fff\"\u003e\n\u003csummary style=\"cursor:pointer;padding:14px 16px;font-weight:600;color:#16201a;font-size:15px;line-height:1.45\"\u003eWhat are the key published studies on tesamorelin?\u003c\/summary\u003e\n\u003cdiv style=\"padding:0 16px 16px\"\u003e\n\u003cp style=\"margin:0 0 10px;color:#5a6157;font-size:15px;line-height:1.6\"\u003e\u003cstrong style=\"color:#16201a\"\u003eFalutz J, et al.\u003c\/strong\u003e \u003cem\u003eN Engl J Med.\u003c\/em\u003e 2007;357(23):2359-2370 — pivotal 26-week phase III, placebo-controlled; measured visceral adipose tissue and IGF-1.\u003c\/p\u003e\n\u003cp style=\"margin:0 0 10px;color:#5a6157;font-size:15px;line-height:1.6\"\u003e\u003cstrong style=\"color:#16201a\"\u003eFalutz J, et al.\u003c\/strong\u003e \u003cem\u003eAIDS.\u003c\/em\u003e 2008;22(14):1719-1728 — 410 patients re-randomised at week 26: continued treatment sustained the VAT change; on discontinuation VAT reaccumulated.\u003c\/p\u003e\n\u003cp style=\"margin:0 0 10px;color:#5a6157;font-size:15px;line-height:1.6\"\u003e\u003cstrong style=\"color:#16201a\"\u003eFalutz J, et al.\u003c\/strong\u003e \u003cem\u003eJ Clin Endocrinol Metab.\u003c\/em\u003e 2010;95(9):4291-4304 — pooled phase 3 dataset behind the label safety table; VAT measured at 26 and 52 weeks.\u003c\/p\u003e\n\u003cp style=\"margin:0 0 10px;color:#5a6157;font-size:15px;line-height:1.6\"\u003e\u003cstrong style=\"color:#16201a\"\u003eStanley TL, et al.\u003c\/strong\u003e \u003cem\u003eJ Clin Endocrinol Metab.\u003c\/em\u003e 2011;96(1):150-158 — the pulsatility paper: GH pulse amplitude and mean overnight GH increased with the pulsatile pattern preserved.\u003c\/p\u003e\n\u003cp style=\"margin:0 0 10px;color:#5a6157;font-size:15px;line-height:1.6\"\u003e\u003cstrong style=\"color:#16201a\"\u003eMakimura H, et al.\u003c\/strong\u003e \u003cem\u003eJ Clin Endocrinol Metab.\u003c\/em\u003e 2012;97(12):4769-4779 — main non-HIV RCT, 12 months: measured VAT, with no significant weight change (P=0.52).\u003c\/p\u003e\n\u003cp style=\"margin:0 0 10px;color:#5a6157;font-size:15px;line-height:1.6\"\u003e\u003cstrong style=\"color:#16201a\"\u003eBaker LD, et al.\u003c\/strong\u003e \u003cem\u003eArch Neurol.\u003c\/em\u003e 2012;69(11):1420-1429 — the positive cognition signal: 137 completers, 20 weeks, favourable effect in healthy and MCI groups; authors called for larger trials.\u003c\/p\u003e\n\u003cp style=\"margin:0 0 10px;color:#5a6157;font-size:15px;line-height:1.6\"\u003e\u003cstrong style=\"color:#16201a\"\u003eStanley TL, et al.\u003c\/strong\u003e \u003cem\u003eLancet HIV.\u003c\/em\u003e 2019;6(12):e821-e830 — 12-month NAFLD trial: measured hepatic fat fraction by imaging; histology left undetermined.\u003c\/p\u003e\n\u003cp style=\"margin:0;color:#5a6157;font-size:15px;line-height:1.6\"\u003e\u003cstrong style=\"color:#16201a\"\u003eEllis RJ, et al.\u003c\/strong\u003e \u003cem\u003eJ Infect Dis.\u003c\/em\u003e 2025;231(5):1230-1238 — negative: open-label phase 2, n=73, six months, between-group P=0.673 on the primary endpoint.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/details\u003e","brand":"ThePeptide","offers":[{"title":"10mg","offer_id":46564291739718,"sku":"TESA-10MG","price":99.99,"currency_code":"CAD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0734\/3020\/4486\/files\/09-12tesamorelin.png?v=1789272471","url":"https:\/\/thepeptide.ca\/products\/tesamorelin-10mg","provider":"ThePeptide","version":"1.0","type":"link"}